A Study of [14C]-LY3537982 in Healthy Participants
Completed · Phase 1 · NCT05901311
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $12,587
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 16
About the trial
- Sponsor
- Eli Lilly and Company (with Loxo Oncology, Inc.)
- Tested
- LY3537982 (drug), [¹⁴C]-LY3537982 (drug), [¹⁴C]-LY3537982 (drug)
- Dates
- Started 2023-06-05; completion 2023-08-10
- Results posted
- Not yet
The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in healthy participants. This study will involve a single dose of 14C radiolabeled LY3537982. This means that a radioactive tracer substance, C14, will be incorporated into the study drug LY3537982 to investigate the study drug and its breakdown products and to find out how much of these passes from blood into urine, feces and expired air. The study will also evaluate the safety and tolerability of LY3537982. The study will be conducted in two parts. The study will last up to 71 days and 61 days for part 1 and 2, respectively.
From ClinicalTrials.gov, last updated 2024-11-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $12,587 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fortrea Clinical Research Unit Inc $12,587
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.